Bone substitute enters orthopaedic trial:
This article was originally published in Clinica
Executive Summary
ETEX, a biomaterials company based in Cambridge, Massachusetts, has begun a US clinical trial of its Alpha-BSM bone substitute material in non-diaphyseal tibia fractures. The product is already cleared in the US for dental, periodontal and craniofacial applications but approval for orthopaedic applications could open it up to a potential $465 million market. The trial will likely be completed by the beginning of next year, said ETEX.